-
Your selected country is
Middle East / Africa
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Product Notices
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
The JES1-5A10 monoclonal antibody specifically binds to the human Interleukin-5 (IL-5). IL-5 is a cytokine that is also known as T-cell replacing factor (TRF), Eosinophil differentiation factor (EDF), and B cell differentiation factor I. IL-5 is produced by T cells, mast cells, and eosinophils. IL-5 controls the generation, differentiation, activation and localization of eosinophils. IL-5 also activates and promotes the differentiation of basophils. IL-5 plays an important role in regulating cell-mediated immunity against parasitic infections and some tumors. High level IL-5 production is involved in some allergic diseases including asthma. IL-5 exerts its biological effects by binding to and signaling through high-affinity heterodimeric IL-5 receptors comprised of transmembrane IL-5 receptor alpha (IL-5Rα, aka, CD125) and beta common (βc, aka, CD131) chains. The βc chain serves as the common signaling subunit for the IL-5 receptor heterodimer as well as for the heterodimeric IL-3 and GM-CSF receptors. The immunogen used to generate the JES1-5A10 hybridoma was recombinant human IL-5. The JES1-5A10 antibody has been reported to cross react with IL-5 from rhesus monkey. This is a neutralizing antibody.
Development References (6)
-
Abrams JS, Roncarolo MG, Yssel H, Andersson U, Gleich GJ, Silver JE. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev. 1992; 127:5-24. (Clone-specific: Neutralization). View Reference
-
Abrams JS, Silver JE, Van Dyke RE, Gleich GI. Eosinophil-active cytokines in human disease: development and use of monoclonal antibodies to IL-3, IL-5 and GMCSF. In: Gleich GJ and Kay AB, ed. Eosinophils in Allergy and Inflammation. New York: Dekker; 1994:133-157.
-
Butterfield JH, Leiferman KM, Abrams J, et al. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood. 1992; 79(3):688-692. (Clone-specific: ELISA, Neutralization). View Reference
-
Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996; 157(3):1261-1270. (Clone-specific: ELISPOT). View Reference
-
Klinman D and Nutman T. ELISPOT assay to detect cytokine-secreting murine and human cells. In: Coligan J, Kruisbeek A, Margulies D, Shevach E, Strober W, ed. Current Protocols in Immunology. 1994:6-19.
-
Schwenger G, Mordvinov V, Fournier R, Czabotar P, Peroni S, Sanderson C. IL-5. In: Oppenheim JJ, Feldmann M, Durum SK. editors in chief, Joost J. Oppenheim, Marc Feldman ; editors, Scott K. Durum .. et al., ed. Cytokine reference : a compendium of cytokines and other mediators of host defense. London: Academic Press; 2001:861-875.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.